| Literature DB >> 32872317 |
Alina Kuryłowicz1, Monika Puzianowska-Kuźnicka1,2.
Abstract
The ongoing obesity pandemic generates a constant need to develop new therapeutic strategies to restore the energy balance. Therefore, the concept of activating brown adipose tissue (BAT) in order to increase energy expenditure has been revived. In mammals, two developmentally distinct types of brown adipocytes exist; the classical or constitutive BAT that arises during embryogenesis, and the beige adipose tissue that is recruited postnatally within white adipose tissue (WAT) in the process called browning. Research of recent years has significantly increased our understanding of the mechanisms involved in BAT activation and WAT browning. They also allowed for the identification of critical molecules and critical steps of both processes and, therefore, many new therapeutic targets. Several non-pharmacological approaches, as well as chemical compounds aiming at the induction of WAT browning and BAT activation, have been tested in vitro as well as in animal models of genetically determined and/or diet-induced obesity. The therapeutic potential of some of these strategies has also been tested in humans. In this review, we summarize present concepts regarding potential therapeutic targets in the process of BAT activation and WAT browning and available strategies aiming at them.Entities:
Keywords: beige adipocyte; brown adipocyte; obesity; thermogenesis; white adipose tissue browning
Mesh:
Year: 2020 PMID: 32872317 PMCID: PMC7504355 DOI: 10.3390/ijms21176241
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Selected molecular mechanisms involved in white adipose tissue browning and brown adipose tissue activation that could constitute potential therapeutic targets for obesity treatment. Stimulation of adrenergic receptors β3 (ADRB3) is crucial for the initiation of thermogenic pathways, leading to the induction of proliferator-activated receptor gamma (PPARγ) coactivator 1α (PGC-1α) and PPARγ. Sirtuin 1 (SIRT1) also activates PPARγ and enables the recruitment of PRDM16 (PR domain containing 16) transcription factor and initiation of the brown fat specific program. These mechanisms regulate the differentiation of beige progenitors toward mature beige adipocytes and the transdifferentiation of white to beige adipocytes. Stimuli activating ADRB3 and SIRT1 are also involved in brown adipocyte differentiation, proliferation, and activation leading to the change from the low-thermogenic toward the high-thermogenic phenotype.
Selected non-pharmacological interventions aiming at white adipose tissue (WAT) browning and brown adipose tissue (BAT) activation.
| Intervention | Mechanism of Action | WAT | BAT | Experimental Model | Reference |
|---|---|---|---|---|---|
|
| |||||
| ↑ ADRB3 | ↑ brown adipocytes | 129Sv mice | [ | ||
| ↑ ADRB3 | ↑ beige adipocytes | clinical study | [ | ||
| capsaicin and cold exposure | ↑ ADRB3 | ↑ beige adipocytes | C57BL/6 mice on high-fat diet | [ | |
| ↓ white adipocytes | ↑ activity | clinical study | [ | ||
|
| |||||
| caloric restriction | ↑ SIRT1 | ↑ beige adipocytes | mice on caloric restriction | [ | |
| capsaicin | ↑ ADRB3 | ↑ beige adipocytes | ↑ brown adipocytes | normal-weight rats | [ |
| ↑ activity | clinical study | [ | |||
| resveratrol | ↑ SIRT1 | ↑ activity | mice on high-fat diet | [ | |
| ↑ AMPK | ↑ beige adipocytes | WAT-derived murine stromal vascular cells | [ | ||
| clinical study | [ | ||||
| ↑ mTOR | ↑ brown adipocytes | 3T3-L1 adipocytes | [ | ||
| curcumin | ↑ AMPK | ↑ beige adipocytes | murine primary white adipocytes | [ | |
| normal-weight mice | [ | ||||
| C57BL/6 mice on high-fat diet | [ | ||||
| ↑ activity | C57BL/6 mice on high-fat diet | [ | |||
| green tea catechins | ↑ PPARγ | ↓white adipocytes | ↑ activity | rats on normal diet | [ |
| ↑ brown adipocytes | clinical study | [ | |||
| berberine | ↑ AMPK | ↑ brown adipocytes | obese db/db mice | [ | |
| ↑ brown adipocytes | clinical study | [ | |||
| PUFA | ↑ ADRB3 | ↑ beige adipocytes | murine white adipocytes | [ | |
| ↑ TRPV | human white adipocytes | [ | |||
| ↑ FFAR4 | ↑ activity | rats on high-fat diet | [ | ||
| ATRA | ↑ RAR | ↑ beige adipocytes | ↑ brown adipocytes | murine white adipocytes | [ |
| = | = | human white adipocytes | [ | ||
| ↑ beige adipocytes | ↑ brown adipocytes | obese rodents | [ | ||
|
| |||||
| ↑ irisin | ↑ beige adipocytes | murine white adipocyte | [ | ||
| ↑ brown adipocytes | C57BL/6 mice on high-fat diet | [ | |||
| ↑ activity | C57BL/6 mice on high-fat diet | [ | |||
| =irisin | =beige adipocytes | clinical study | [ | ||
| ↑ IL-6 | ↑ beige adipocytes | murine white adipocyte | [ | ||
| ↑ beige adipocytes | mice on high-fat diet | [ | |||
| ↑ FGF21 | ↑ FFA oxidation | ↑ activity | mice with diet-induced obesity | [ | |
| ↑ activity | clinical study | [ | |||
|
| |||||
| ↑ type 2 cytokine signaling | ↑ beige adipocytes | obese | [ | ||
| mice on high-fat diet | [ | ||||
| ↑ lactate | ↑ beige adipocytes | murine and human white adipocyte | [ | ||
|
| |||||
| ↑ bile acids | ↑ beige adipocytes | ↑ activity | clinical studies | [ | |
| microbiota | ↑ beige adipocytes | ↑ activity | clinical studies | [ |
↑ increase/enhancement; ↓ decrease/reduction; ADRB3—adrenergic receptor beta 3; AMPK—AMP-activated protein kinase; ATRA—all-trans retinoic acid; FFA—free fatty acids, FFAR4—free fatty acids receptor 4; FGF21—fibroblast growth factor 21; IL-6—interleukin 6, mTOR—mammalian target of rapamycin; PPARγ—proliferator-activated receptor gamma; PUFA—polyunsaturated fatty acids; SIRT1—sirtuin 1; TRPV—transient receptor potential vanilloid.
Selected pharmacological approaches aiming at white adipose tissue (WAT) browning and brown adipose tissue (BAT) activation.
| Intervention | Compound | Mechanism of Action | WAT | BAT | Experimental Model | Ref |
|---|---|---|---|---|---|---|
|
| CL-316243 | ↑ PGC-1α | ↑ lipolysis | ↑ brown adipocytes | C57BL/6 mice | [ |
| isoprenaline | = | = | clinical study | [ | ||
| mirabegron | = | ↑ activity | clinical study | [ | ||
|
| rosiglitazone | ↑ PRDM16 | ↑ beige adipocytes | ↑ activity | C57BL/6 mice | [ |
| ↑ beige adipocytes | C57BL/6 mice | [ | ||||
| GQ-16 | ↑ beige adipocytes | ↑ brown adipocytes | mice on high-fat diet | [ | ||
| imatinib | ↑ beige adipocytes | C57BL/6 mice | [ | |||
| pioglitazone | ↓ brown adipocytes | clinical study | [ | |||
|
| fenofibrate | ↑ PRDM16 | ↑ beige adipocytes | mice with diet-induced obesity | [ | |
| pemafibrate | ↑ beige adipocytes | ↑ activity | mice with diet-induced obesity | [ | ||
|
| A-769662 | ↑ PGC-1α | ↑ beige adipocytes | ↑ activity | obese | [ |
| ↑ beige adipocytes | ↑ activity | AMPK KO mice | [ | |||
| AICAR | ? | ↑ energy dissipation | white rat adipocytes | [ | ||
| cordycepin | ? | ↑ beige adipocytes | ↑ activity | mice on high-fat diet | [ | |
| liraglutide | ↑ NO | ↑ beige adipocytes | ↑ activity | mice on high-fat diet | [ | |
|
| resveratrol | ↑ PPARγ | ↑ beige adipocytes | ↑ activity | mice on high-fat diet and 3T3-L1 adipocytes | [ |
| ↑ AMPK | ↑ beige adipocytes | WAT-derived murine stromal vascular cells | [ | |||
| SRT501, SRT1720 | ↑ PGC-1α | ↑ activity | mice on high-fat diet | [ | ||
|
| empagliflozin | ↑ M2 macrophages | ↑ beige adipocytes | mice with diet-induced obesity | [ | |
|
| miR-455 | ↑ HIF1an | ↑ beige adipocytes | ↑ brown adipocytes | human white adipocytes | [ |
| miR-92a | ? | ↓ activity | clinical study | [ |
↑ increase/enhancement; ↓ decrease/reduction; ? unknown mechanism; ADRB3—adrenergic receptor beta 3; AICAR—5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; AMPK—AMP-activated protein kinase; HIF1an—hypoxia inducible factor 1 α subunit inhibitor; NO—nitric oxide; PPAR—proliferator-activated receptor; PGC-1α—PPARγ coactivator 1α; PRDM16—PR domain containing 16 transcription factor; SGLT2i—sodium-glucose cotransporter 2 inhibitors; SIRT1—sirtuin 1.